ReviewJournal of clinical medicine2019
Circulating miRNAs as Biomarkers for Endometriosis and Endometriosis-Related Ovarian Cancer-An Overview.
Review in Journal of clinical medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 67 citations in OpenAlex.
- Exosomal miR-22-3p targets p53 to regulate endometrial epithelial cell function in the pathogenesis of endometriosis.Journal of molecular histology · 2026Article
- Epigenetics, Oxidative Stress, and the Microbiome in Endometriosis: Toward an Integrated Mechanistic Framework for Precision Medicine.Journal of personalized medicine · 2026Review
- Anatomic subtype-specific causal effects of endometriosis on ovarian cancer: a two-sample Mendelian randomization study.Discover oncology · 2025Article
- Prediction of genomic biomarkers for endometriosis using the transcriptomic dataset.World journal of clinical cases · 2025Article
- Diagnostic Value and Molecular Function of MicroRNAs in Endometrial Diseases: A Systematic Review.Cancers · 2024Review
- Immune pathway through endometriosis to ovarian cancer.World journal of clinical oncology · 2024Review
- Endometriosis-Related Ovarian Cancer: Where Are We Now? A Narrative Review towards a Pragmatic Approach.Journal of clinical medicine · 2024Review
- Advances in research on malignant transformation of endometriosis-associated ovarian cancer.Frontiers in oncology · 2024Review
- miRNA Expression Profiles in Ovarian Endometriosis and Two Types of Ovarian Cancer-Endometriosis-Associated Ovarian Cancer and High-Grade Ovarian Cancer.International journal of molecular sciences · 2023Article
- TNFα-Induced Altered miRNA Expression Links to NF-κB Signaling Pathway in Endometriosis.Inflammation · 2023Article
- TNFα-induced altered miRNA expression links to NF-κB signaling pathway in endometriosis.Research square · 2023Article
- The Expression ofInternational journal of molecular sciences · 2023Article
- Apoptosis, inflammation, and oxidative stress in infertility: A mini review.Toxicology reports · 2023Review
- Endometriosis Stem Cells as a Possible Main Target for Carcinogenesis of Endometriosis-Associated Ovarian Cancer (EAOC).Cancers · 2022Review
- Role of serum microRNAs as biomarkers for endometriosis, endometrioid carcinoma of ovary & endometrioid endometrial cancer.The Indian journal of medical research · 2022Article
- Exosomal MicroRNA as Biomarkers for Diagnosing or Monitoring the Progression of Ovarian Clear Cell Carcinoma: A Pilot Study.Molecules (Basel, Switzerland) · 2022Article
- Endometriosis in para-aortic lymph node resembling a malignancy: a case report and literature review.BMC women's health · 2022Review
- Pan-Cancer Analysis of BUB1B/hsa-miR-130a-3p Axis and Identification of Circulating hsa-miR-130a-3p as a Potential Biomarker for Cancer Risk Assessment.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- miRNAs and lncRNAs: Potential Non-Invasive Biomarkers for Endometriosis.Biomedicines · 2021Review
- Circulating Exosomal miRNAs as Biomarkers in Epithelial Ovarian Cancer.Biomedicines · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early detection and accurate diagnosis are pivotal in the management of endometriosis and endometriosis-related ovarian neoplasms (ERONs), yet there is no clear common ground regarding their pathogenesis. Endometriosis is a debilitating pathology that profoundly impairs the quality of life. Although the spontaneous resolution of endometriosis is possible, studies suggest that it can be a progressive condition, and ERONs can develop. The gold standard for diagnosis remains as the invasive method of laparoscopy followed by histological confirmation. In recent years, novel biomarkers have been discovered. MicroRNAs (miRNA) represent important epigenetic modulators of gene expression and are very attractive as biomarkers due to their lower complexity, tissue specificity, and stability in bodily fluids. Several studies have advanced the possibility of miRNAs becoming potential biomarkers in endometriosis and ERONs. Our aim is to bring these studies together in order to have a better understanding of whether, how, and when miRNAs might be used as biomarkers for these pathologies.
methodsWe selected the reviewed papers from Google Academic, PubMed, and CrossRef. A total of eight studies met the inclusion criteria.
resultsMiR-200 family, miR-143, 145, miR-20a, and miR199a were the most commonly dysregulated miRNAs in endometriosis, and miR-200 family was found to be dysregulated in both ERONs and endometriosis.
conclusionsNo single miRNA was considered as a sole biomarker for this pathology. However, since the prognostic value of biomarkers is generally enhanced if more are assessed at the same time, a panel of miRNAs could be a better indicator of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.